An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners
Advances in Therapy · 2025
DOI: 10.1007/s12325-025-03250-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Therapy, 2025. Verfasst von Jothydev Kesavadev und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jothydev's Diabetes and Research Centre, Trivandrum, Kerala, India. jothydev@gmail.com. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Insulin, Diabetes Mellitus, Type 2, Diabetes Mellitus. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
The management of diabetes has seen significant advancements with the introduction of various injectable therapies. Being a common chronic disorder, it is managed by doctors across all specialties worldwide. Despite the availability of new medications, healthcare professionals continue to face ambiguity due to differing terminologies and variations in regional practices. This review aims to elucidate the current therapeutic spectrum of injectable therapies in diabetes care, providing clarity on the types, mechanisms, and clinical implications of both insulin and non-insulin injections. An extensive review of existing literature was conducted, focusing on insulin injections (including short-acting, rapid-acting, ultra-rapid acting, intermediate-acting, long acting and ultra-long-acting types), non-insulin injections (such as glucagon-like peptide-1 [GLP-1] receptor agonists, dual GLP-1 and gastric inhibitory polypeptide [GIP] agonist, and amylin analogs) and co-formulations (long-acting insulin with GLP-1 or long-acting insulin with rapid acting insulin). We have included innovators and biosimilars in this review article for better understanding. Insulin therapies offer tailored glycemic control, while non-insulin injectables provide additional benefits in weight management and reduced hypoglycemia risk. This review serves as a comprehensive guide for healthcare providers worldwide to navigate the landscape of injectable treatment options in diabetes, with a focus on optimizing therapeutic outcomes through informed decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jothydev's Diabetes and Research Centre, Trivandrum, Kerala, India. jothydev@gmail.com.
- Jothydev's Diabetes and Research Centre, Trivandrum, Kerala, India.
- Dia Care-Diabetes Care and Hormone Clinic, Diabetology, Ahmedabad, Gujarat, India.
- Madras Diabetes Research Foundation and Dr. Mohan's Diabetes Specialties Centre, Chennai, India.
- Joshi Clinic, Lilavati and Sir HN RF Hospitals, Mumbai, Maharashtra, India.
- Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.
Zitieren
APA
Kesavadev, J., Basanth, A., Shankar, A., Saboo, B., Mohan, A. R., Joshi, S., Ghosh, S., Krishnan, G., Jothydev, K., & Ashik, A. (2025). An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners. Advances in Therapy. https://doi.org/10.1007/s12325-025-03250-3
Vancouver
Kesavadev J, Basanth A, Shankar A, Saboo B, Mohan AR, Joshi S, et al. An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners. Advances in Therapy. 2025. doi:10.1007/s12325-025-03250-3
BibTeX
@article{Kesavadev2025,
author = {Kesavadev, Jothydev and Basanth, Anjana and Shankar, Arun and Saboo, Banshi and Mohan, Anjana Ranjit and Joshi, Shashank and Ghosh, Sujoy and Krishnan, Gopika and Jothydev, Krishnadev and Ashik, Asha},
title = {An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-025-03250-3}
}
EUVIMED